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Abstract
The composition of the mitochondrial membrane is important for
its architecture and proper function. Mitochondria depend on a
tightly regulated supply of phospholipid via intra-mitochondrial
synthesis and by direct import from the endoplasmic reticulum.
The Ups1/PRELI-like family together with its mitochondrial chaper-
ones (TRIAP1/Mdm35) represent a unique heterodimeric lipid
transfer system that is evolutionary conserved from yeast to man.
Work presented here provides new atomic resolution insight into
the function of a human member of this system. Crystal structures
of free TRIAP1 and the TRIAP1–SLMO1 complex reveal how the
PRELI domain is chaperoned during import into the intermembrane
mitochondrial space. The structural resemblance of PRELI-like
domain of SLMO1 with that of mammalian phoshatidylinositol
transfer proteins (PITPs) suggest that they share similar lipid trans-
fer mechanisms, in which access to a buried phospholipid-binding
cavity is regulated by conformationally adaptable loops.
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Introduction
Mitochondria are dynamic organelles involved in a variety of cellu-
lar processes, such as energy production via oxidative phosphoryla-
tion and the biosynthesis of ATP, which is fundamental for cell
viability. Mitochondria also play important roles in the cell
cycle, cellular differentiation and programmed cell death. They can
orchestrate cell death (apoptosis) via release of cytochrome c and
activation of the caspase signalling, which is essential for normal
cellular development and tissue homoeostasis. Cancers often display
dysregulation in apoptosis, contributing to the generation of chemo-
therapy-resistant cells. Thus, mitochondria are central to a plethora
of cellular processes both under normal physiological circumstances
and in disease.
Mitochondrial function requires a highly coordinated supply of
proteins and phospholipids. The majority of mitochondrial proteins
are synthesised on cytosolic ribosomes and then imported to the
intermembrane space (IMS) by the translocase of the outer
membrane (TOM complex) [1]. Small cysteine-rich proteins enter
the mitochondrial intermembrane space assembly (MIA) pathway,
which comprises the necessary disulphide-transferring machinery
for folding and translocation into the IMS [2,3].
Phospholipid composition, transport and membrane allocation
are essential for mitochondrial homoeostasis. Some of these are
common in all cellular membranes, such as phosphatidylethanol-
amine (PE) or phosphatidylcholine (PC), but others are exclusive to
mitochondria, such as cardiolipin (CL). Biosynthesis of PE and CL
occurs in mitochondria, whereas PC is synthesised in the endoplas-
mic reticulum and then imported into the organelle either as the
final product or as precursors for other lipids. Phosphatidylserine
(PS) is imported at the mitochondria-associated domains of the
endoplasmic reticulum and is the major source for PE synthesis
within mitochondria. CL synthesis occurs exclusively at the inner
membrane via a sequence of enzymatic steps starting with phospha-
tidic acid (PA) [4]. In Saccharomyces cerevisiae, the family of Ups
proteins (Ups1–3; [5]) control the accumulation of CL and PE within
mitochondria [6–8]. Ups1 was first discovered as a necessary factor
for the development of proper mitochondria morphology [5], but
was subsequently associated with phospholipid metabolism [7,9].
In yeast mitochondria, Ups1 and Ups2 form tight complexes with
Mdm35 and together, they regulate the subsequent biosynthesis of
CL and PE. Mdm35 is a small ~9-kDa protein that possesses a twin
CX9C sequence motif. Ups1 and Ups2 are intrinsically unstable and
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are readily degraded by the mitochondrial proteases, Yme1 and
Atp23; however, in the presence of Mdm35, they are stabilised and
accumulate in the IMS [10,11]. The primary function of Mdm35/
Ups complexes is to mediate the transfer of phospholipid PA from
the mitochondrial outer membrane (MOM) to the inner membrane
(MIM), where these phospholipids act as principal precursors for
the synthesis of CL [6,7]. There is also evidence that these
complexes may aid the re-export of PE back to the MOM [12].
The evolutionary conservation of the Mdm35/Ups system across
all eukaryotic life highlights its importance in cellular viability by
maintaining mitochondrial lipid homoeostasis. Humans possess four
principal homologues of the Ups family, namely PRELID1 (also
known as PRELI), PRELID2, SLMO1 and SLMO2 (also termed
PRELID3a and PRELID3b) [13]. All share a conserved domain of
unknown structure, called ‘PRELID’ (Protein of Relevant Evolution-
ary and Lymphoid Interest Domain; pfam: PF04707) [13–15]. The
Mdm35 homologue in mammals is TRIAP1 (TP53-regulated inhibi-
tor of apoptosis 1; alias p53CSV, p53-inducible cell-survival factor).
Although it was originally identified outside mitochondria after acti-
vation by p53 during mild genotoxic stress [16], later experiments
established an evolutionary conserved function in complex with
PRELID1 for PA transfer across the intermembrane space of mito-
chondria [8]. TRIAP1 thus contributes to the maintenance of cardio-
lipin (CL) levels in the inner mitochondrial membrane of human
cells, thereby sequestering cytochrome c and stalling apoptosis [8].
Interestingly, it was also shown that the loss of the TRIAP1/
PRELID1 complex could be complemented with excess PG, which
can also be used to synthesise CL, presumably via another pathway.
The identification of Mdm35/Ups and TRIAP1/PRELID complexes
as lipid transfer systems provided first insight as to how lipids are
shuttled between mitochondrial membranes. Our understanding of
the interplay between TRIAP1-PRELID assembly, bilayer targeting
and intermembrane lipid exchange is limited, as an atomistic view
of the key stages in mitochondrial phospholipid transfer is lacking.
Work presented here provides new structural insight into PRELI
domain family, their interaction with mitochondrial chaperone
TRIAP1 and phospholipid transfer. Crystal structures of free TRIAP1
and the TRIAP1-SLMO1 complex reveal how PRELI-like domains
could be stabilised during mitochondrial import and the location
of a buried phospholipid-binding site. Mutagenesis experiments
identify a role of charged amino acids for phospholipid transfer and
a lipid exchange loop, akin to that found in mammalian phosphati-
dylinositol transfer proteins, which plays a role in phospholipid
extraction.
Results and Discussion
TRIAP1 forms a twin helical bundle with an unusually
hydrophobic surface
TRIAP1 possesses a twin CX9C motif that is predicted to form two
disulphide bonds within the oxidising environment of mitochondrial
IMS [17]. To examine the folded state of TRIAP1, we crystallised it
as a fusion protein with maltose-binding protein (MBP) and using
the coordinates of MBP to provide initial phases, we solved its high-
resolution structure (Fig EV1 and Table 1). The structure reveals
the characteristic a-helical hairpin motif that is stapled together by
two disulphide bonds located at C8-C47 and C18-C37 (Fig 1A).
Electron density was not observed for the C-terminal 18 amino acid
residues suggesting a degree of conformation heterogeneity or flexi-
bility in this region. To shed further light on this, we recorded
heteronuclear NMR data and completed the resonance assignment
of full-length TRIAP1 and a short version that was truncated imme-
diately after the coiled coil region using standard triple resonance
methodology (Fig 1B). NMR chemical shift and NOE data confirm
the helical coiled coil and the arrangement of the twin CX9C motifs
observed in the crystal structure. In the 2D 1H-15N spectrum of full-
length TRIAP1, a significant number of peaks are observed within a
narrow range of 1H chemical shifts in the centre of the spectrum.
These amide peaks are also much sharper than those present in heli-
cal regions. These were assigned to the C-terminus, and their
elevated transverse 15N relaxation times, as evidenced by narrow
line widths, indicate that the C-terminal region (after K53) is highly
disordered and dynamic on a pico- to nanosecond timescale
(Fig 1B).
The tandem CX9C motif is a common template used by other
important chaperones (i.e. Mia40 and Cox11) [17] that play diverse
roles in the biogenesis of mitochondrial proteins. While CX9C
proteins do not have a traditional hydrophobic core, their functional
features are usually appended to flexible N- or C-termini. The best
characterised is Mia40 which promotes oxidative folding of
substrates via an N-terminal CPC motif that is responsible for a
disulphide exchange mechanism [18]. Mia40 introduces the first
disulphide bond into other CX9C proteins trapping them within the
IMS, for example this has been shown for Cox17, which after oxida-
tion of its second disulphide, copper(I), is bound via its N-terminal
CC motif and delivered to receptive copper proteins [19].
Oxidation of the twin CX9C motifs in TRIAP1, and its subsequent
folding, is also believed to be promoted by Mia40, which produces
an identical arrangement of the two helices (Fig 1C). A striking
difference in the structure of TRIAP1 is the prominence of an exposed
hydrophobic stripe running the full length of the CX9C coiled coil
domain (Fig 1D). This solvent-exposed hydrophobic surface is domi-
nated by a series of stacked aromatic side chains conserved in all
TRIAP1 homologues (Fig 1E), suggesting that this represents part of
the interaction surface for the recruitment of PRELI-like proteins.
Remarkably, this extensive hydrophobic surface does not induce
specific multimerisation of TRIAP1 when free in solution, as NMR
line widths (Fig 1B) and gel filtration chromatography profiles are
consistent with a monomeric species under the conditions used in
this study. It is conceivable that the concaved shape of the surface
frustrates the association of monomers, but provides a complemen-
tary assembly surface for induced folding of PRELI-like domains,
which remain unstructured in the absence of its chaperone and then
are rapidly degraded by mitochondrial proteases.
TRIAP1 interacts with SLMO1 via its hydrophobic stripe
To assess the role of the solvent-exposed, hydrophobic stripe on the
interaction between TRIAP1 and PRELI-like domain proteins, we co-
expressed His-tagged versions of PRELID1, PRELID2, SLMO1
(PRELID3a) or SLMO2 (PRELID3b) with MBP-TRIAP1 and isolated
the complexes by affinity and size-exclusion chromatography in the
absence of phospholipid. Crystals were obtained for the apo
TRIAP1-SLMO1 complex with several diffracting to 3.6 A˚, and the
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Figure 1. Crystal structure of TRIAP1.
A Cartoon representation in green for the crystal structure of TRIAP1 showing the location of the disulphide bonds (yellow) and the twin CX9C motifs.
B 1H-15N HSQC NMR spectrum of TRIAP1DC (blue) overlaid on a single 1H-15N HSQC NMR spectrum of full-length TRIAP1 from a 15N-transverse relaxation
measurement series (red). The relaxation delay for the time point in the 15N-transverse relaxation experiment was set such that all 15N-signals for the folded coiled
coil have decayed and therefore would not be observed in the spectrum. Remaining signals observed represent amides with slow transverse relaxation and therefore
are highly dynamic and disordered. Assignment of the 1H-15N HSQC spectra reveals that this flexible region is localised to the C-terminus of full-length TRIAP1.
C Cartoon representation for the superposition of TRIAP1 with the solution structure of Mia40 revealing topological similarity of the twin CX9C-coiled coil domain.
D Conserved hydrophobic stripe on the surface of TRIAP1 comprising conserved aromatic residues. The conserved V4 residue in the N-terminus of helix I is also shown.
Backbone of TRIAP1 is shown as a cartoon and stacked aromatic side chains labelled in stick representation. Shading of side chains according to alignment shown in (E).
E Protein sequence alignment for TRIAP1, Mdm35 and selected homologues. Positions of experimentally determined and predicted a-helices are indicated above the
alignment. Disulphide bond connectivities are also indicated. Red shading indicates invariant residues across the homologues, and yellow shading indicates locations
where there are conserved residues in three homologues.
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structure was solved by molecular replacement again using the MBP
structure. Four copies of the TRIAP1-SLMO1 complex are present in
the asymmetric unit (Fig EV1), and Table 1 summarises the statis-
tics for the processing and refinement data.
The structure reveals an intimate interaction between the hydro-
phobic stripe on the TRIAP1 chaperone and the PRELI-like domain
(Fig 2). The TRIAP1-binding region on SLMO1 is delineated by the
region between residues P13 and L39, which encompasses the edge
b2 strand, an ordered proline-rich loop and the a1-helix (Fig 2B).
The cluster of three phenylalanine residues at the tip of the TRIAP1
coiled coil structure (F19, F23 and F28) interacts with a hydrophobic
cluster delineated by M22, V38 and L49 on SLMO1. A second
hydrophobic patch comprises V33, L34 and V36 from SLMO1
together with F41, Y44, V48 and I52 from the other end of the
hydrophobic strip on TRIAP1 (Fig 2C, left). To probe the relative
importance of residues at this interface, we performed site-directed
mutagenesis and assessed the formation of the TRIAP1-SLMO1
complex using pull-down assays via a His-tag on the SLMO1
(TRIAP1 was untagged). We were unable to detect complex forma-
tion when either V36 or L49 in SLMO1 was mutated to alanine,
while mutation of the neighbouring V38 and a double mutant of
V33A/L34A left the complex intact (Fig 2D, left). Somewhat surpris-
ingly, the TRIAP1-SLMO1 complex could be detected for single point
mutants at aromatic residues in TRIAP1, but the double mutant of a
key interfacial contact, TRIAP1-F41A/SLMO1-V38A (Fig 2C),
abrogated complex formation (Fig 2D, right). These data provide
convincing evidence for the interface identified in our structural
studies and highlight the key hydrophobic interactions stabilising
the complex. Although the hydrophobic stripe on TRIAP1 seems
somewhat tolerant to mutation, this tallies with its role as a chaper-
one, in that the overall shape and hydrophobicity of the interac-
tional surface are important for its ability to binding a series of
related but not identical PRELI-like substrates.
Although the arrangement of the twin CX9C coiled coil motifs is
highly similar, the structures of free and SLMO1-bound TRIAP1
diverge at the termini, outside the region delineated by the disul-
phide bonds. The first turn of the N-terminal helix (a1) is unwound
in the structure of the complex and forms an extended region that
interacts with the edge b2 strand of SLMO1. V4 in TRIAP1 becomes
sandwiched in a conserved hydrophobic cluster delineated by L34
(b2), L54 (b3) and Y77 (b4) from SLMO1. V4 is also stabilised in this
position by the formation of an ST-turn [20] in which the side chain
from invariant S3 forms hydrogen bond with the amide G5, two resi-
dues ahead (Fig 2C, right). Although this transition may be due to
crystal contact forces, it is interesting to note that human TRIAP1 is
acetylated in vivo; therefore, capping of the charged N-terminus (as
is mimicked in our MBP fusion protein) could contribute to the inter-
action with PRELI-like domain [21]. Acetylating of the yeast version
Table 1. Crystallographic data and refinement statistics for free TRIAP1 and the TRIAP1-SLMO1 complex.
Crystal parameters TRIAP1 TRIAP1-SLMO1 complex
Space group P21 P1
Cell dimensions (Å) a = 75.4, b = 56.0, c = 100.3
b = 106.4
a = 79.6, b = 80.9, c = 98.0
a = 87.3, b = 85.6, c = 89.9
Molecules per asymmetric unit 2 8
Data collection
Beamline DLS I03 DLS I03
Wavelength (Å) 0.98 0.98
Resolution (Å) 2.12–48.41 (2.12–2.18) 3.58–97.62 (3.58–3.67)
Unique observations 45,307 (3,176) 28,326 (2,108)
Rmerge 0.093 (0.585) 0.108 (0.544)
<I>/rI 9.3 (2.2) 11.6 (2.7)
Completeness (%) 98.7 (94.0) 98.9 (98.7)
Redundancy 3.6 (3.2) 3.5 (3.5)
Average B value (Å2) 35.5 85.6
Refinement
Rwork/Rfree (%) 19.8/24.2 27.5/30.9
Protein residues in asymmetric unit 841 2,218
Number of ligands 2 maltose 4 maltose
Number of waters 266 0
Rmsd stereochemistry
Bond length (Å) 0.013 0.011
Bond angles (ᵒ) 1.47 1.66
Ramachandran analysis
Residues in favoured regions 98.8% 96.3%
Residues in allowed regions 100% 100%
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Figure 2. Crystal structure of the apo TRIAP1-SLMO1 complex.
A Cartoon representation for the crystal structure of the TRIAP1-SLMO1 complex. TRIAP1 is shown in green and SLMO1 in orange with annotated secondary structure
elements.
B Highlighted TRIAP1-SLMO1 interface with a superimposition of free TRIAP1 (grey) and bound TRIAP1 (green). The hydrophobic side chains of TRIAP1 are in green
sticks, and the complementary interaction region on SLMO1 is shown as red cartoon. The rest of SLMO1 is shown as an orange cartoon.
C Hydrophobic interaction at the TRIAP1-SLMO1 interface. Left: cartoon representation of the TRIAP1-SLMO1 complex with key interfacial hydrophobic side chains
shown as sticks and labelled with residue numbers. TRIAP1 is coloured green, and the complementary interaction region on SLMO1 is shown as red cartoon with the
remaining sequence of SLMO1 shown as an orange cartoon. Right: hydrophobic contacts to the N-terminal V4 from TRIAP1.
D SDS–PAGE analysis of His-tag pull-down assays with His-SLMO1 and TRIAP1. For each sample, the column flow through (FT) and elution (EL) fraction are shown.
SLMO1 mutants are shown in the left panel, and the lack of recovery of mutant complexes V36A and L49A suggests that these alterations disrupt the formation of the
complex. TRIAP1 mutants are shown on the right, and while mutant complex can be purified for the single mutants, the complex is lost when F41A in TRIAP1 is
accompanied by V38A in SLMO1.
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has yet to be reported, but the N-terminus of Mdm35 is significantly
longer (Fig 1E). The C-terminal helix (a2) of TRIAP1 appears more
concaved in the complex and extended by an additional turn that
also contacts SLMO1, although as with free TRIAP1, no density was
observed beyond this at the C-terminus.
Translocation of TRIAP1/Mdm35 into the IMS is believed to be
driven by cysteine oxidation of their CX9C motifs by the MIA path-
way [3], where they function as acceptor proteins that are critical
for the successful import of the PRELI-like proteins [10,11]. After
mitochondrial import by the outer membrane (TOM complex),
PRELI-like domains dock onto TRIAP1/Mdm35 and are stabilised.
In the absence of their chaperone, they are unstable and are readily
degraded enzymatically by mitochondrial proteases. The exposed
hydrophobic surface of TRIAP1 together with the disulphide-stapled
coiled coil domain would provide a sturdy assembly platform to
initiate PRELID folding by stabilising structure formation at the
N-terminus. Speculatively, this arrangement would suggest that the
N-terminal segment emerges from the TOM complex into the IMS
and is immediately captured by TRIAP1 and subsequent folding of
the PRELIDs would aid completion of their import.
PRELI-like domains contain a hydrophilic cavity important for
phospholipid transfer
The PRELI-like domain of SLMO1 exhibits 28% identity (41% simi-
larity) and 27% identity (38% similarity) with equivalent regions
within Ups1 and PRELID1 (Fig 3A), respectively, which are known
to facilitate PA transfer activity in vitro and supply PA to the inner
mitochondrial membrane [8]. The high conservation enables us to
homology model both Ups1 and PRELID1 on our structure to exam-
ine whether the SLMO proteins are likely to promote phospholipid
transfer between membranes (Fig EV2). The folded PRELI-like
domains of SLMO1, Ups1 and PRELID1 comprise a large concaved
7-stranded b-sheet decorated by three helices on one side (Fig 2),
which encapsulates a hydrophilic cavity within the core (Fig 3B).
Several highly conserved charged residues (namely K24, R53, E80
and E108 in SLMO1) are located proximal to the cavity (Fig 3B).
R53, E80 and E108 are invariant across the PRELID family, while
K24 is conserved in both Ups1 and PRELID1 (Fig 3A). We therefore
postulate that this internal cavity is the likely site for accommodat-
ing the charged phospholipid head group of PA. To examine
whether TRIAP1-SLMO1 can also exert phospholipid transfer activ-
ity, we measured PA transfer in a fluorescence dequenching assay
in the presence of increasing protein concentrations (Fig 3C).
Despite the activity of TRIAP1-SLMO1 being lower than for Mdm35-
Ups1, a clear dose-dependent increase in PA transfer from donor to
acceptor vesicles is observed in vitro.
To explore the influence of the conserved charged residues on
phospholipid transfer by PRELI-like domains, we decided to test
mutants at these positions for function. As the activity of yeast
Mdm35-Ups1 is significantly higher than TRIAP1-SLMO1 and it
remains the best characterised system in terms of available func-
tional assays, we created the mutant series in Ups1 at the equivalent
positions, namely R25, R54, E80 and E108. Many of the mutant
Mdm35-Ups1 complexes suffered reduced yields when expressed
under identical conditions to wild-type. Mutant complexes that
could be obtained in sufficient amounts, which included R25A,
R25K, R54E, E108A and E108K, were initially screened for PA
transfer at a fixed concentration in our fluorescence dequenching
assay (Fig EV3). All mutations had measurable deleterious effects
on PA transfer and identify a contributory role for these charged
amino acids. As Mdm35-Ups1 R54E produced yields of monodi-
spersed pure complex comparable to wild-type, we concluded that
substantial destabilisation of the mutant complex is unlikely and a
stable interaction of mutant Ups1 with Mdm35 is observed in its
soluble state. We therefore chose this mutant for further purification
for quantitative analysis of phospholipid transfer and membrane
binding in a liposome floatation assay. The transport of PA by the
R54E mutant is reduced to ~60% of the native complex (Fig 3D). In
the liposome floatation assay, wild-type Mdm35-Ups1 partially
dissociates upon by binding PA-containing liposomes and a fraction
of Mdm35 is present in aqueous solution, while the rest is associ-
ated with Ups1 in the membrane (Fig 3E). Dissociation of Mdm35
could facilitate a deeper penetration of Ups1 into the membrane for
efficient loading PA, before re-associating during extraction for
subsequent diffusion to the acceptor membrane. The R54E mutant
complex dissociates far more readily when interacting with the
donor membranes, and Mdm35 is found exclusively in the aqueous
fraction (Fig 3E). One explanation for this observation is that the
mutation hinders a full productive interaction with PA within the
membrane and is therefore captured and the interaction with
Mdm35 is less efficient (Fig 3E). Interestingly, R54 (R53 in SLMO1)
is located at one end of cavity proximal to the Mdm35 interface
(Fig 3B) and may therefore play a role in signalling the reformation
of the Mdm35-Ups1 interface after PA loading.
The PRELI-like domain of SLMO1 resembles mammalian
phosphatidylinositol transfer proteins
Despite no significant sequence homology, the PRELI-like domain
shows a remote structural similarity to other lipid-binding proteins
including the phosphatidylinositol transfer proteins (PITPs) [22] and
the related cholesterol-binding START domains [23]. Phosphatidyl-
inositol transfer proteins (PITP) are ubiquitous in all mammalian
tissues and highly conserved (> 98% identity) [22]. The primary
member of this family, PITPa, is a multifunctional protein with
regulatory roles in intracellular lipid and vesicular trafficking and in
lipid-mediated signal transduction pathways. High-resolution struc-
tures are available for both lipid-loaded and apo forms of PITPa
[24,25]. Figure 4 illustrates the superposition of the lipid-loaded and
apo forms of PITPa onto the modelled structure of the Mdm35-Ups1
complex, for which functional mutagenesis experiments were
performed. As for the PRELI-like domain, two helices face the inte-
rior of the central b-sheet and surround a lipid-binding core of
PITPa, which also feature a prominent hydrophilic cavity [24,25]. In
the PITPa structures, a lipid exchange loop is present between the
third and fourth strand that lies at one end of the b-sheet (Fig 4A
and B). In the apo form, this loop is partially unravelled and is
postulated to insert into the lipid bilayer and help anchor the protein
to the target membrane. Following phospholipid loading and release
from the membrane, this region undergoes a major conformation
change and together with the C-terminal helical region closes the
lipid-PITPa structure and releases it from the membrane (Fig 4B).
The equivalent region to this lipid exchange loop in the PRELI-like
domain is located between b3 and b4 and encompasses loops L4
and L5 together with the intervening helix a2. Although this region
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Figure 3. The phospholipid head group-binding cavity within SLMO1.
A Protein sequence alignment for the PRELI domain protein family. Positions of secondary structural elements and loops for SLMO1 are numbered above the alignment.
Numbering for the S. cerevisia Ups1 sequence is indicated below the alignment. The locations of the charge and loop mutations are highlighted with magenta and
blue triangles, respectively. Interface mutations are highlighted with green triangles. Red shading indicates invariant residues across the homologues, and yellow
shading indicates locations where there are conserved residues in at least four homologues.
B Left panel: cut-through of the solvent-exposed surface for SLMO1 revealing the partially hydrophilic cavity. SLMO1 surface is coloured orange with positive and
negative charge residues coloured blue and red, respectively. Right panel: cartoon representation showing four conserved charged side chains that are proximal to
the cavity.
C NBD-PA transfer by the TRIAP1-SLMO1 complex. Donor liposomes (12.5 lM; DOPC/DOPE/CL/Lac-PE/NBD-PA/Rhod-PE = 50/18/15/10/5/2%) and acceptor liposomes
(50 lM; DOPC/DOPE/CL/Lac-PE/DOPA = 50/20/15/10/5%) were incubated for 5 min with indicated concentration of TRIAP1-SLMO1 and the NBD fluorescence was
monitored. Values were normalised to the NBD fluorescence of liposomes lacking quenching Rhod-PE.
D PA transfer for native and R54E Ups1-Mdm35 complexes. Upper panel: NBD-PA transfer by the Ups1-Mdm35 complex and Ups1R54E-Mdm35. Donor liposomes
(12.5 lM; DOPC/DOPE/CL/Lac-PE/NBD-PA/Rhod-PE = 50/28/5/10/5/2%) and acceptor liposomes (50 lM; DOPC/DOPE/CL/Lac-PE/DOPA =50/30/5/10/5%) were incubated
for 5 min with 10 nM of Ups1-Mdm35 or mutant, and the NBD fluorescence was monitored. Values were normalised to the NBD fluorescence of liposomes lacking
quenching Rhod-PE. Lower panel: quantitative assessment of the transport activity. Values are represented as the number of NBD-PA transported per complex in a
minute. Columns and error bars indicate the mean  SD. n = 4. Student’s t-test was used to calculate P-values. **P < 0.01.
E Binding to PA-containing liposomes. Purified Ups1-Mdm35 complex or its mutant variant was incubated with liposomes composed of DOPC/POPE/DOPA (50/30/20%),
and binding was assessed by flotation of liposomes in a sucrose gradient. Upper panel: fractions after sucrose gradient were analysed by SDS–PAGE and CBB
staining. All liposomes were recovered in the upper two fractions. Lower panel: quantification of Ups1 and Mdm35. Signals in upper two fractions (bound) or lower
two fractions (unbound) were quantified and are represented as a fraction in total signals of all four fractions.
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is partially disordered in our crystal structure of TRIAP1-SLMO1 in
the absence of phospholipid, the defined regions superpose better
with the PITP-bound structure, which may indicate smaller confor-
mation changes in the PRELI-like domain upon lipid binding.
Furthermore, this loop exhibits flexibility in unbound forms; there-
fore, the precise conformation seen in a crystal structure may not
reflect the dynamic ensemble that exists in solution. We postulated
that this loop might also assist in regulating the interaction and
insertion of Ups1/PRELI-like proteins into the phospholipid bilayer
and interact with the hydrophobic acyl chains, akin to the PITP
proteins. To test this notion, we created a double mutant in two
conserved amino acids of Ups1 in this loop, namely L62 and W65,
A B
C D
Figure 4. PRELI domains are structurally similar to mammalian phosphatidylinositol transfer proteins.
A Cartoon representation for the superposition of the modelled Mdm35-Ups1 structure (blue and red, respectively) with apo mouse PITPa (pdb: 1KCM; green). The
identified lipid exchange loop in PITPa and equivalent region in Ups1 (L4-a2-L5) are indicated.
B Cartoon representation for the superposition of the modelled Mdm35-Ups1 structure (blue and red, respectively) with phosphatidylcholine-bound rat PITPa (pdb:
1T2Z; brown). Conformational changes in lipid exchange loop and the C-terminal helical lid (indicated by arrows) close the structure and cap the bound phospholipid.
C Liposome binding. Purified Mdm35-Ups1 complex or its mutant variant was incubated with liposomes composed of DOPC/POPE/DOPA (50/30/20%), and binding was
assessed by flotation of liposomes in a sucrose gradient. Upper panel: fractions after sucrose gradient were analysed by SDS–PAGE and CBB staining. All liposomes
were recovered in the upper two fractions. Lower panel: quantification of Ups1 and Mdm35. Signals in upper two fractions (bound) or lower two fractions (unbound)
were quantified and represented as a fraction of total signals of four fractions.
D NBD-PA extraction. Purified Mdm35-Ups1 complexes (80 nM) were incubated with liposomes (4 lM) composed of DOPC/POPE/NBD-PA/Rhod-PE (50/43/5/2%) filled
with 12.5% sucrose. After incubation at 25°C for 2 min, liposomes were sedimented by an ultracentrifugation step (200,000× g, 30 min) and NDB fluorescence in the
supernatant fraction was quantified using standard probes of NBD-PA. Columns and error bars indicate the mean  SD. n = 3.
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to reduce the overall hydrophobicity, with the purpose of perturbing
the interaction with lipid acyl chains or any necessary conforma-
tional changes.
The location of these L62 and W65 interfaces is distant from the
Mdm35 interface and is therefore not expected to affect the intrinsic
stability of the complex. Furthermore, expression yields and size-
exclusion chromatography profiles are highly similar to the native
complex (Fig EV3A). We then tested this loop mutant in the lipo-
some flotation assay (Fig 4C) to examine the interaction of the
complex with PA-containing membranes. As seen for the charge
R54E mutant, Mdm35 is found exclusively in the aqueous fraction,
while Ups1-L62A/W65A remains bound to liposomes. A conse-
quence of this would be a noticeable decrease in the amount of PA
extracted from the donor membrane (Fig 4D). Although we cannot
rule out completely that the mutation lowers the intrinsic affinity of
Mdm35 for Ups1, the results suggest that this loop, as in PITPs,
could contribute to lipid exchange by closing access to the Ups1
cavity and sequestering PA. In the wild-type complex, Mdm35 is
able to capture the PA-loaded Ups1 complex and facilitates diffusion
to the acceptor membrane. While this Ups1 mutant still binds accep-
tor membranes efficiently, it is less able to form a productive
complex with PA for extraction, possibly by preventing the confor-
mational changes necessary for closing the complex and departing
the membrane surface. The presence of Mdm35 in both membrane-
bound and soluble fractions for the wild-type complex suggests an
active role for Mdm35/TRIAP1 in regulating phospholipid capture,
extraction and delivery. Interestingly, the C-terminal helical region
of PITPs, which also helps stabilise the closed soluble form, is
partially unwound in the apo form but refolds and reorients upon
lipid loading. Although this region is not present in SLMO1, it coin-
cides with the N-terminal helix of TRIAP1 in the complex (Fig 4).
This arrangement is also consistent with a regulatory role for
Mdm35/TRIAP1.
The Mdm35-Ups1 complex catalyses trafficking of PA from the
mitochondrial outer membrane to the innermembrane, where it
serves as a phospholipid precursor for CL biosynthesis. Consequently,
yeast strains with a ups1 deletion exhibit low CL levels [5,7,9]. To
probe the effect of our mutations in the function of Mdm35-Ups1
in vivo, we complemented Dups1 yeast strain with selected Ups1
mutants and measured cardiolipin levels (Fig 5A). Consistent with
the previous observations, a significant reduction in CL is evident in
the Dups1, which can be restored with wild-type Ups1 expressed from
a plasmid. Notably, cells carrying the Ups1-R54E and L62A/W65A
mutations showed significantly reduced level of CL, presumably as a
result of the reduced availability of its precursor PA.
Our study on TRIAP1-SLMO1 and Mdm35-Ups1 extends our
current understanding of how PRELID-assisted phospholipid
transfer may take place (Fig 5B). Once imported into the IMS, the
distinctive concaved arrangement of stacked aromatic and hydro-
phobic residue on the surface of TRIAP1 provides a template for
A B
Figure 5. In vivo analysis of Ups1-mutant yeast strains and suggested mechanism of assisted PA transfer by PRELI-like domains.
A Restoration of CL levels by plasmid-encoded Ups1 and its mutant variants. Dups1 cells carrying empty vector (YCplac111ADH, vector) or a plasmid encoding indicated
Ups1 variants were grown to logarithmic phase in YP medium supplemented with 2% galactose. Cells were collected and subjected to lipid extraction and
phospholipidome analysis. CL levels were represented as a proportion in total phospholipids. Wild-type cells carrying empty vector were analysed as a control.
Columns and error bars indicate the mean  SD. n = 3. Student’s t-test was used to calculate P-values. **P < 0.01.
B Proposed mechanism of phosphatidic acid (PA) transport by PRELI-like domains. Phospholipid transport between mitochondrial inner and outer membranes (MIMs &
MOMs) catalysed by TRIAP1/Mdm35-PRELID complexes: (a) import of PRELID and degradation by mitochondrial proteases if no complex formed; (b) folding of PRELI-
like domain on the TRIAP1/Mdm35 twin coiled-coiled CX9C motif; (c) donor bilayer (MOM) binding and preloading by the complex; (d) PA loading and dissociation of
TRIAP1/Mdm35; (e) recapture of loaded PRELID by TRIAP1/Mdm35, donor bilayer binding and delivery of PA; (f) degradation of PRELID at the MIM; and (g) biosynthesis
of cardiolipin (CL) from PA.
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PRELID folding and the stability to maintain a buried cavity.
Although the absence of a phospholipid-bound PRELID structure
in our study renders the precise function role for residues delin-
eating this cavity somewhat speculative, a recent study reporting
the crystal structure of a PA-bound conformation Mdm35-Ups1
complex provides the finer details of phosphate recognition [26].
The cavity bears hydrophilic character, which may suggest that it
accommodates the phospholipid head group, with access being
regulated by the flexible hydrophobic loops at one end of the
structure. The integrity and stability of this complex is essential
for preserving mitochondrial PRELID concentrations after import
and the initial targeting to the phospholipid bilayer. The complex
is subsequently destabilised upon membrane association, and
TRIAP1 is released, which presumably facilitates deeper bilayer
penetration by the PRELID and a more intimate interaction with
the substrate phospholipid for loading; TRIAP1/Mdm35 then likely
recaptures a fully loaded, closed PRELID within the IMS and
assists in its diffusion to the MIM, in which the cargo lipid is
delivered. Although no direct structure evidence is available, we
imagine that conformational changes in the lipid-loaded complex
facilitate specific targeting to the MIM, either through recognition
of a specific component (i.e. a protein) or through a more generic
feature of membrane composition, such as the charge or curva-
ture.
Materials and Methods
Cloning, expression and purification
Full-length TRIAP1 (residues 1–76), a C-terminal truncation
(TRIAP1DC; residues 1–56) and SLMO1 (residues 1–172) were
amplified from codon-optimised genes (Invitrogen) and cloned into
the N-terminal His6 vectors pET-46 Ek/LIC (Novagen; TRIAP1) and
pRSF-2 Ek/LIC vector (Novagen; SLMO1)). SLMO1 mutants, V33A/
L34A, V36A, V38A and L49A, and full-length TRIAP1 mutants,
F23A, F28A and F41A, were made using the Q5 site-directed muta-
genesis kit (NEB) and cloned into vectors pRSF-2 Ek/LIC (Novagen;
SLMO1) and pETDuet-1 (Novagen; TRIAP1), which included no
affinity tag for this cloning site. TRIAP1 (residues 2–76) was also
cloned as a C-terminal fusion with MBP (MBP-TRIAP1) into the
vector pMALX(E) [27]. These were transformed alone (TRIAP1) or
together (MBP-TRIAP1 or untagged TRIAP1 with SLMO1) into
E. coli Shuffle T-7 strain (NEB) and expressed in either LB media or
M9 media supplemented with 13C-glucose and/or 15NH4Cl. These
were purified using nickel-affinity chromatography followed by
gel filtration with either a Superdex-75 (TRIAP1) or Superdex-
200 (MBP-TRIAP1-SLMO1 complex) column (GE healthcare)
pre-equilibrated in 20 mM Tris-HCl pH 8, 200 mM NaCl or 20 mM
Tris-HCl pH 8, 200 mM NaCl and 40 mM D-(+)-maltose, respec-
tively.
NMR resonance assignment
Full-length TRIAP1 (300 ll) in 50 mM sodium phosphate pH 6.5,
50 mM NaCl and 10% D2O was used to record standard triple reso-
nance experiments (HNCACB, CBCACONH, HNCO, HN(CA)CO)
[28] on a Bruker 600 spectrometer equipped with TXI cryoprobe at
303 K. Backbone assignments (95%) were achieved using NMRview
supplemented with in-house scripts [29]. 15N T2 relaxation series
was measured for full-length TRIAP1 in its free state [30]. NMR
assignments were complete on full-length TRIAP1 and were subse-
quently transferred to the C-terminal truncated version, TRIAP1DC,
by superposition of the 1H-15N HSQC NMR spectra.
Crystallisation, data collection, structure solution
and refinement
Crystals of MBP-TRIAP1 (10 mg/ml) and MBP-TRIAP1/SLMO1
complex (25 mg/ml) in 10 mM Tris–HCl pH 8, 50 mM NaCl and
5 mM D-(+)-maltose were crystallised using sitting-drop vapour
diffusion at 293 K in either 100 mM sodium acetate pH 4.6, 25%
(w/v) PEG 4000, 18% (w/v) MPD and 200 mM ammonium sulphate
or 100 mM sodium formate pH 7.0 and 12% (w/v) PEG 3350,
respectively. Crystals of MBP-TRIAP1 were directly flash-frozen in
liquid N2, while crystals of MBP-TRIAP1/SLMO1 complex were first
briefly washed in 100 mM sodium formate pH 7.0, 15% (w/v) PEG
3350 and 25% (w/v) PEG 200 prior to freezing. Diffraction data
were collected at 100 K on beamline I03 of the Diamond Light
Source (DLS), UK. Data were processed using XDS [31] and scaled
with SCALA [32]. Molecular replacement was performed in PHASER
[33] using the structure of MBP (pdb: 1hsj) as the search model. For
MBP-TRIAP1, 5% of the reflections was omitted for cross-valida-
tion, density modification was performed with PARROT [34], and
automated model building was carried out with ARPWARP [35].
TLS and NCS refinement was then carried out using REFMAC [36],
and model building was carried out in COOT [37]. For MBP-
TRIAP1/SLMO1 complex, iterations of density modification in
PARROT, automated model building with BUCCANEER [38] and
manual model manipulation in COOT were performed. This was
followed by iterations of PARROT, simultaneous 8-fold cross-crys-
tal averaging between MBP envelopes and envelopes of MBP from
the crystal structure of MBP-TRIAP1 and 4-fold NCS averaging
each between MBP, TRIAP1 and SLMO1 envelopes, followed by
model building in COOT. When map quality could not be
improved any further, refinement was carried out in REFMAC
using TLS, secondary structure, jelly body, map sharpening and
NCS restraints, with model building carried out in COOT. Process-
ing and refinement statistics for the final model can be found in
Table 1. The 3D models of the Ups1-Mdm35 and TRIAP1-PRELID1
complexes were constructed using the protein structure thread-
ing program PHYRE [39] and were refined independently with
ModRefiner [40].
Functional analysis of lipid transfer protein complexes in vitro
Lipid-binding floatation experiments as well as the lipid transport
assay of NBD-PA by Ups1-Mdm35 were performed as previously
described [6,11]. NBD-PA transport by TRIAP1-SLMO1 complex
was assayed in buffer M (40 mM MES-KOH, pH 5.5, 150 mM
NaCl, 1 mM EDTA). To assess the ability of Ups1-Mdm35 and its
mutant variants to extract PA from membrane, 80 nM protein
was incubated with liposomes that constitute of 50% DOPC, 38%
of DOPE, 5% of CL, 5% of NBD-PA and 2% of Rhodamine-PE
(filled with 12.5% sucrose, total lipid concentration is set to
4 lM) for 2 min at 25°C in assay buffer (20 mM Tris-HCl, pH 7.4,
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250 mM NaCl, 2 mM EDTA, total assay mixture was set to
240 ll). After incubation, 80 ll of the transport mixture was
taken and mixed with 40 ll of 0.1% Triton X-100, and then, NBD
and Rhodamine fluorescence was measured. The rest of the
mixture was subjected to an ultracentrifugation step (200,000 × g,
30 min) to sediment liposomes, and then, 80 ll of the superna-
tant was taken and mixed with 40 ll of 0.1% Triton X-100. NBD
fluorescence in the supernatant was measured, and the values
were converted to the amount of NBD-PA by setting the values
from the total mixture before sedimentation step to 100%
(48 pmol). Rhodamine fluorescence was used to assess the
contamination of the liposomes to the supernatant.
Mass-spectrometric lipid analysis
Mass-spectrometric analysis was performed essentially as described
[6] with some optimisation especially for the analysis of CL in whole
yeast cells. Lipids were extracted from yeast cells grown in YP
media supplemented with 2% galactose in the presence of internal
standards of major phospholipids (PC 17:0-14:1, PE 17:0-14:1, PI
17:0-14:1, PS 17:0-14:1, PG 17:0-14:1, PA 17:0-14:1 all from Avanti
Polar Lipids) and CL (CL mix I, Avanti Polar Lipids LM-6003).
Extraction was performed according to Bligh and Dyer with modi-
fications. Briefly, 0.5 OD600 unit cells were resuspended in 250 ll
water and mixed with 1 ml of chloroform/methanol/25% HCl
[40:80:0.6 (v/v)] with lipid standards in a glass vial. 300 ll glass
beads were added to the vial, and cells were treated by rigorous
mixing for 30 min at room temperature. After this step, lipid
extraction was performed according to standard Bligh and Dyer
protocol. The solvent from the final chloroform phase was evapo-
rated by a gentle stream of argon at 37°C. Lipids were dissolved
in 10 mM ammonium acetate in methanol and analysed on a
QTRAP 6500 triple quadrupole mass spectrometer (SCIEX)
equipped with nano-infusion spray device (TriVersa NanoMate,
Advion). CL species were identified in positive ion mode by scan-
ning for precursors of the masses corresponding DAG-H2O frag-
ments as singly charged ions. Other phospholipid species were
identified as previously described [6] with some optimisation for
the nano-infusion device according to Ozbalci et al [41]. Mass
spectra were processed by the LipidView software version 1.2
(SCIEX) for identification and quantification of lipids. Correction
of isotopic overlap in CL species was performed according to
Scherer et al [42]. Lipid amounts (pmol) were corrected for
response differences between internal standards and endogenous
lipids.
Accession codes
The coordinates for the crystal structures of TRIAP1 and the
TRIAP1-SLMO1 complex have been deposited in the Protein Data
Bank with PDB ID codes 4xzs and 4xzv.
Expanded View for this article is available online:
http://embor.embopress.org
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